Edwards Lifesciences Corporation [NYSE: EW] plunged by -$1.07 during the normal trading session on Wednesday and reaching a high of $73.525 during the day while it closed the day at $71.95. The company report on August 28, 2023 at 8:10 AM that EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE.
Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.
Bernard Zovighian, chief executive officer, and Scott B. Ullem, chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/. An archived version of the webcast will be available later that day on the Edwards investor relations website.
Edwards Lifesciences Corporation stock has also loss -1.67% of its value over the past 7 days. However, EW stock has declined by -21.01% in the 3 months of the year. Over the past six months meanwhile, it has lost -11.97% and lost -3.57% year-on date.
The market cap for EW stock reached $44.23 billion, with 606.90 million shares outstanding and 602.73 million shares in the current float. Compared to the average trading volume of 3.17M shares, EW reached a trading volume of 3284910 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Edwards Lifesciences Corporation [EW]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $97.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 19, 2023.
The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 1.51, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 7.82. The Price to Book ratio for the last quarter was 6.85, with the Price to Cash per share for the same quarter was set at 2.46. Price to Free Cash Flow for EW in the course of the last twelve months was 64.85 with Quick ratio for the last quarter at 2.30.
EW stock trade performance evaluation
Edwards Lifesciences Corporation [EW] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.67. With this latest performance, EW shares dropped by -5.74% in over the last four-week period, additionally sinking by -11.97% over the last 6 months – not to mention a drop of -19.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 29.86, with the RSI for the last a single of trading hit 27.67, and the three-weeks RSI is set at 31.69 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 80.53, while it was recorded at 73.03 for the last single week of trading, and 81.59 for the last 200 days.
Edwards Lifesciences Corporation [EW]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +31.63 and a Gross Margin at +78.31. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +28.28.
Return on Total Capital for EW is now 26.14, given the latest momentum, and Return on Invested Capital for the company is 23.46. Return on Equity for this stock inclined to 26.14, with Return on Assets sitting at 18.12. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 11.91. Additionally, EW Total Debt to Total Capital is recorded at 10.64, with Total Debt to Total Assets ending up at 8.34. Long-Term Debt to Equity for the company is recorded at 11.47, with the Long-Term Debt to Total Capital now at 10.25.
Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $87,971 per employee. Receivables Turnover for the company is 7.89 with a Total Asset Turnover recorded at a value of 0.64.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 3.20.
Earnings per share (EPS) analysis for Edwards Lifesciences Corporation [EW] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 9.67%.
Edwards Lifesciences Corporation [EW]: Institutional Ownership
The top three institutional holders of EW stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in EW stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in EW stock with ownership which is approximately 5.7381%.